To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Enoxaparin does not significantly reduce rates of deep vein thrombosis after TKA

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
August 2013

Enoxaparin does not significantly reduce rates of deep vein thrombosis after TKA

Vol: 2| Issue: 7| Number:524| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

VenaFlow plus Lovenox vs VenaFlow plus Aspirin for Thromboembolic Disease Prophylaxis in Total Knee Arthroplasty

J Arthroplasty. 2006 Sep;21(6 Suppl 2):139-43.

Contributing Authors:
Geoffrey H Westrich Friedrich Bottner Russell E Windsor Richard S Laskin Steven B Haas Thomas P Sculco

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

275 patients undergoing unilateral total knee arthroplasty were randomized to receive spinal epidural anaesthesia, VenaFlow compression device, and enoxaparin or spinal epidural anaesthesia, VenaFlow compression device, and aspirin to prevent deep vein thrombosis. Enoxaparin and aspirin were taken for 4 weeks after surgery. Deep vein thrombosis was diagnosed through ultrasonography completed 3 to ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue